Related Experiment Videos
Age-specific differences in oncogenic pathway deregulation seen in human breast tumors
Carey K Anders1, Chaitanya R Acharya, David S Hsu
1Division of Medical Oncology, Department of Medicine, Duke University, Durham, North Carolina, USA.
Plos One
|January 3, 2008
Summary
Breast cancer in young women has distinct biology, driven by specific signaling pathway deregulation. Understanding these unique molecular patterns improves prognosis and targets treatment strategies for this aggressive disease.
Area of Science:
- Oncology
- Genomics
- Molecular Biology
Background:
- Breast cancer exhibits varied behavior based on patient age.
- Younger women often experience more aggressive breast cancer subtypes.
- Distinct biological drivers may underlie age-related differences in breast cancer.
Purpose of the Study:
- To elucidate the specific biological mechanisms driving aggressive breast cancer in young women.
- To identify unique molecular signatures associated with early-onset breast cancer.
- To compare oncogenic pathway deregulation between young and older breast cancer patient cohorts.
Main Methods:
- Analysis of Affymetrix microarray data from 411 early-stage breast cancer patients.
- Stratification into age-specific cohorts: young (≤45 years) and older (≥65 years).
- Evaluation of gene set enrichment analysis (GSEA), oncogenic pathway signatures, and chemotherapy sensitivity predictors.
Main Results:
- Younger women showed higher probabilities of PI3K and Myc pathway deregulation.
- Specific patterns of pathway deregulation (low Src/E2F, high PI3K/Myc/beta-catenin) conferred worse prognosis in young women (HR=4.15).
- Conversely, high Src/E2F and low PI3K/Myc/beta-catenin predicted poorer outcomes in older women (HR=2.7).
Conclusions:
- Breast cancer in young women is a distinct biological entity.
- Unique deregulated signaling pathways are prognostic, independent of clinical factors.
- Findings support refining targeted therapies for younger breast cancer patients.
Related Concept Videos
mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
Interactions Between Signaling Pathways
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Cancers Originate from Somatic Mutations in a Single Cell
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Adaptive Mechanisms in Cancer Cells
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...